HIRE HEALTHCARE WRITERS PROMOTIONAL MEDICAL WRITER MANUSCRIPT MEDICAL BLOG PRESENTATIONS 醫學作家香港 NEWS AND PRESS HEALTHCARE WRITERS

MediPaper News

• Trastuzumab-biosimilar Ontruzant® FDA approved in several indications 21st January 2019
  On 18 January 2019, the FDA approved the Herceptin®-biosimilar Ontruzant® (trastuzumab-dttb, Samsung BioEpsis), a HER2/neu receptor antagonist, for patients with HER2-overexpressing (HER2+) breast cancer in the adjuvant and metastatic setting, and in metastatic HER2+ gastric cancer patients. Ontruzant® was approved as biosimilar, not as an interchangeable product.
• ERAS guidelines for antenatal and preoperative care in caesarean delivery 21st January 2019
  The Enhanced Recovery after Surgery (ERAS) Society recently published Part 1 of the Society's 3-part caesarean delivery guidelines, focussed on pre-operative care for women undergoing scheduled and unscheduled caesarean delivery, in the American Journal of Obstetrics & Gynecology. Caesarean delivery is the most common surgical procedure in the modern world.
• Cabozantinib FDA approved in HCC patients failing sorafenib 17th January 2019
  On 14 January 2019, the FDA approved cabozantinib (Cabometyx®, Exelixis) for hepatocellular carcinoma (HCC) patients previously treated with sorafenib.
• Erasmus University MC investigating a new surgical matrix to reduce post-operative complications 16th January 2019
  The synthetic and fully resorbable TIGR®Matrix surgical mesh (Novus Scientific AB, Uppsala − Sweden) might be an interesting candidate for the prevention of complications frequently observed with permanent mesh placement, according to Professor Johan Lange of the Erasmus University in Rotterdam − the Netherlands.
• Keytruda® FDA approved for recurrent and metastatic Merkel cell carcinoma 14th January 2019
  On 19 December 2018, pembrolizumab (Keytruda®, Merck) received accelerated approval by the FDA for the treatment of recurrent locally advanced or metastatic (R/M) Merkel cell carcinoma (MCC) in adult and paediatric patients.
• Calaspargase pegol-mknl (Asparlas®) FDA approved in paediatric and young adult acute lymphoblastic leukaemia (ALL) patients 27th December 2018
  On 20 December 2018, the FDA approved the asparagine specific enzyme calaspargase pegol-mknl (Asparlas®, Servier) as a component of multi-agent chemotherapeutic regimens for the treatment of paediatric and young adult patients aged 1 month to 21 years with acute lymphoblastic leukaemia (ALL).
• Elzonris™ FDA approved for blastic plasmacytoid dendritic cell neoplasm (BPDCN) 27th December 2018
  On 21 December 2018, the FDA approved the CD123-directed cytotoxin tagraxofusp-erzs (Elzonris™, Stemline Therapeutics), for the treatment of adult and paediatric patients of 2 years and older with blastic plasmacytoid dendritic cell neoplasm (BPDCN).
• Awake, Sedated or Anaesthetised for Regional Anaesthesia Block Placements 26th December 2018
  ©Aspen PharmacareThere is no excerpt because this is a protected post.
• Closed-Loop or Automated Titration of IV Anaesthesia: Impact on Routine Anaesthesia 24th December 2018
  ©Aspen PharmacareThere is no excerpt because this is a protected post.
• Olaparib (Lynparza) FDA approved as maintenance for BRCAm ovarian cancer 22nd December 2018
  On 19 December 2018, the FDA approved olaparib (Lynparza®, AstraZeneca) as a maintenance treatment for adult advanced epithelial ovarian, fallopian tube or primary peritoneal cancer patients who achieving a complete or partial response to first-line platinum-based chemotherapy and who have deleterious germline or somatic BRCA-mutatations (gBRCAm or sBRCAm) by an FDA-aproved test or who are suspected […]